Poly(ADP-ribose) Polymerase Inhibitors

"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.

Descriptor ID	D000067856
MeSH Number(s)	D27.505.519.389.739 D27.505.954.248.692
Concept/Terms	Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerase Inhibitors Inhibitors of Poly(ADP-ribose) Polymerases Poly(ADP-ribosylation) Inhibitors PARP Inhibitors Inhibitors, PARP

Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Poly(ADP-ribose) Polymerase Inhibitors [D27.505.519.389.739]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Poly(ADP-ribose) Polymerase Inhibitors [D27.505.954.248.692]

Below are MeSH descriptors whose meaning is related to "Poly(ADP-ribose) Polymerase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 17 publications over 10 distinct years, with a maximum of 4 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2013	0	1	1
2016	0	1	1
2019	0	1	1
2020	1	1	2
2021	3	1	4
2022	0	2	2
2024	1	0	1
2025	1	2	3
2026	1	0	1

Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.

Du M, Peng P, Cao D, Cheng N, Yao L, Sun Y, Li J, Zhang H, Lou G, Tang J, Wang D, Wang Y, Zhang G, Xiang Y. Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study. J Ovarian Res. 2026 Jan 26; 19(1).

View in: PubMed
Fonteyne V, Tree A, Castro E, Touijer K, Walz J. Prostate cancer. Lancet. 2026 Feb 07; 407(10528):622-636.

View in: PubMed
Peng M, Lee S, Nair HG, MacGilvary N, Cong K, Kraemer M, Li R, McConnell J, Baer C, Deng B, Zhu L, Cantor SB. RAD51 is chromatin enriched and targetable in BRCA1-deficient cells. Mol Cell. 2025 Sep 18; 85(18):3373-3387.e6.

View in: PubMed
Whalen JM, Earley J, Silva C, Mercurio AM, Cantor SB. Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability. Nat Cancer. 2025 Feb; 6(2):278-291.

View in: PubMed
MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 12; 144:103775.

View in: PubMed
Bhardwaj PV, Abdou YG. Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. Curr Oncol Rep. 2022 12; 24(12):1791-1800.

View in: PubMed
Cong K, Cantor SB. Exploiting replication gaps for cancer therapy. Mol Cell. 2022 07 07; 82(13):2363-2369.

View in: PubMed
Rizzo A, Mollica V, Merler S, Morelli F, Sorgentoni G, Oderda M, Santoni M, Massari F. Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. Expert Opin Drug Metab Toxicol. 2022 Mar; 18(3):235-240.

View in: PubMed
Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, And?jar-S?nchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021 11 18; 81(22):4692-4708.e9.

View in: PubMed
Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021 08 05; 81(15):3128-3144.e7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals